Skip to main content

Clinical and immunological features of rheumatoid arthritis patients with positive anti-centromere antibody: a case-control study

Journal
Frontiers in medicine (Q1)
Published
30 July 2026
Study design
Case-control study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Xiuqing Yan, Meili Wang, Fengmei Ge, Linyi Peng, Xuebin Wang, Li Wang
PMID
42597341
DOI
10.3389/fmed.2026.1882422

Why clinicians should know about it

  • Picked for Rheumatology (paper of the day, 19 August 2026): ACA‑positive RA phenotype, lung & sicca risk

Abstract

OBJECTIVE: To characterize the clinical and immunological features of rheumatoid arthritis (RA) patients with positive anti-centromere antibody (ACA). METHODS: In this retrospective case-control study, the clinical manifestations, demographic data, and immunological test results of these patients were collected and analyzed. RESULTS: ACA-positive RA patients exhibited a significantly higher prevalence of Raynaud's phenomenon (15.0% vs. 2.5%, χ 2 = 4.838, P = 0.028), xerostomia (22.5% vs. 8.8%, χ 2 = 4.363, P = 0.037), xerophthalmia (27.5% vs. 10.0%, χ 2 = 6.128, P = 0.013), and interstitial pneumonia (27.5% vs. 5.0%, χ 2 = 12.343, P < 0.001), as well as higher rates of elevated ALP (18.9% vs. 1.3%, χ 2 = 9.780, P = 0.002) and GGT (33.33% vs. 15.0%, χ 2 = 5.086, P = 0.024). CONCLUSION: ACA-positive RA may present a unique phenotype characterized by an increased risk of interstitial lung disease, sicca symptoms, and cholestatic liver injury; thus, enhanced pulmonary/hepatic screening and tailored monitoring strategies are critical.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.